What data sources does EL7.AI use?

EL7.AI uses official data from the Federal Reserve (FOMC), European Central Bank, CFTC (COT reports), BLS, FRED, FMP for prices, and 15+ news sources.

What is the DLS system?

Dictionary-based Linguistic Scoring — a proprietary tone analysis system using a dictionary of 800+ categorized phrases. Reproducible and verifiable results, unlike random AI analysis.

How is EL7.AI different from Bloomberg?

Bloomberg takes years to master and costs $25,000/year. EL7.AI offers the same institutional data with built-in AI analysis at $500/year, with full Arabic support.

What markets are covered?

Stocks from 7 exchanges (NYSE, NASDAQ, LSE, TSE, HKSE, Euronext, XETRA, Tadawul), 28 forex pairs, 300+ cryptocurrencies, 50+ indices, and 40+ commodities.

Is EL7.AI available in Arabic?

Yes! EL7.AI is an Arabic-first platform — everything is available in Arabic with full RTL support: interface, analysis, news, and reports.

How much does EL7.AI cost?

Founding member pricing starts at $500/year (Batch 1). The price is locked forever at this level. Regular pricing will be $1,000/year after official launch.

Is there a refund policy?

Yes — full refund within 7 days of purchase. If you're not satisfied, contact us for a complete refund.

Bank of Japan and Bank of England with DLS, advanced crypto module, enhanced trading signals, and mobile app. All future features are included in your subscription.

Hims & Hers Downgraded as GLP-1 Regulatory and Legal Risks Intensify

Hims & Hers Health (HIMS) has seen its stock rating downgraded to 'hold' as the company faces mounting regulatory and legal challenges that threaten its growth trajectory. The downgrade comes ahead of its upcoming earnings report, driven by the potential closure of the GLP-1 compounding loophole used for weight-loss treatments. Federal agencies, including the FDA and the Department of Justice (DOJ), are increasing scrutiny over the distribution and compounding of these drugs. Furthermore, aggressive litigation from Novo Nordisk has significantly altered the company's risk profile and speculative upside. While the core telehealth business remains steady, the removal of the GLP-1 growth catalyst is forcing a valuation reset for the stock. Investors are now cautious as the shifting legal landscape threatens the premium multiple previously enjoyed by the company.

Hims & Hers Downgraded as GLP-1 Regulatory and Legal Risks Intensify

Instruments